135 related articles for article (PubMed ID: 29440889)
1. A novel therapeutic strategy for cartilage diseases based on lipid nanoparticle-RNAi delivery system.
Wang S; Wei X; Sun X; Chen C; Zhou J; Zhang G; Wu H; Guo B; Wei L
Int J Nanomedicine; 2018; 13():617-631. PubMed ID: 29440889
[TBL] [Abstract][Full Text] [Related]
2. Enhanced hepatic delivery of siRNA and microRNA using oleic acid based lipid nanoparticle formulations.
Wang X; Yu B; Ren W; Mo X; Zhou C; He H; Jia H; Wang L; Jacob ST; Lee RJ; Ghoshal K; Lee LJ
J Control Release; 2013 Dec; 172(3):690-8. PubMed ID: 24121065
[TBL] [Abstract][Full Text] [Related]
3. siRNA therapy in osteoarthritis: targeting cellular pathways for advanced treatment approaches.
Li Y; Zhao J; Guo S; He D
Front Immunol; 2024; 15():1382689. PubMed ID: 38895116
[TBL] [Abstract][Full Text] [Related]
4. The Niemann-Pick C1 Inhibitor NP3.47 Enhances Gene Silencing Potency of Lipid Nanoparticles Containing siRNA.
Wang H; Tam YY; Chen S; Zaifman J; van der Meel R; Ciufolini MA; Cullis PR
Mol Ther; 2016 Dec; 24(12):2100-2108. PubMed ID: 27633442
[TBL] [Abstract][Full Text] [Related]
5. Combinatorial therapeutic approaches with RNAi and anticancer drugs using nanodrug delivery systems.
Babu A; Munshi A; Ramesh R
Drug Dev Ind Pharm; 2017 Sep; 43(9):1391-1401. PubMed ID: 28523942
[TBL] [Abstract][Full Text] [Related]
6. Lipid nanoparticle mediated small interfering RNA delivery as a potential therapy for Alzheimer's disease.
Ahmed T
Eur J Neurosci; 2024 Jun; 59(11):2915-2954. PubMed ID: 38622050
[TBL] [Abstract][Full Text] [Related]
7. Which Lipid Nanoparticle (LNP) Designs Work? A Simple Kinetic Model Linking LNP Chemical Structure to In Vivo Delivery Performance.
Roh EH; Sullivan MO; Epps TH
ACS Appl Mater Interfaces; 2024 Mar; 16(11):13399-13410. PubMed ID: 38466900
[TBL] [Abstract][Full Text] [Related]
8. Structure and Function of Cationic and Ionizable Lipids for Nucleic Acid Delivery.
Sun D; Lu ZR
Pharm Res; 2023 Jan; 40(1):27-46. PubMed ID: 36600047
[TBL] [Abstract][Full Text] [Related]
9. A potent bioreducible ionizable lipid nanoparticle enables siRNA delivery for retinal neovascularization inhibition.
Cao X; Su L; Chen H
Eur J Pharm Biopharm; 2024 Jun; 199():114296. PubMed ID: 38636882
[TBL] [Abstract][Full Text] [Related]
10. Technologies for investigating the physiological barriers to efficient lipid nanoparticle-siRNA delivery.
Shi B; Abrams M
J Histochem Cytochem; 2013 Jun; 61(6):407-20. PubMed ID: 23504369
[TBL] [Abstract][Full Text] [Related]
11. The landscape of nanoparticle-based siRNA delivery and therapeutic development.
Moazzam M; Zhang M; Hussain A; Yu X; Huang J; Huang Y
Mol Ther; 2024 Feb; 32(2):284-312. PubMed ID: 38204162
[TBL] [Abstract][Full Text] [Related]
12. Nanoparticle-encapsulated siRNAs for gene silencing in the haematopoietic stem-cell niche.
Krohn-Grimberghe M; Mitchell MJ; Schloss MJ; Khan OF; Courties G; Guimaraes PPG; Rohde D; Cremer S; Kowalski PS; Sun Y; Tan M; Webster J; Wang K; Iwamoto Y; Schmidt SP; Wojtkiewicz GR; Nayar R; Frodermann V; Hulsmans M; Chung A; Hoyer FF; Swirski FK; Langer R; Anderson DG; Nahrendorf M
Nat Biomed Eng; 2020 Nov; 4(11):1076-1089. PubMed ID: 33020600
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of nucleotide trafficking during siRNA delivery to endothelial cells using perfluorocarbon nanoemulsions.
Kaneda MM; Sasaki Y; Lanza GM; Milbrandt J; Wickline SA
Biomaterials; 2010 Apr; 31(11):3079-86. PubMed ID: 20092889
[TBL] [Abstract][Full Text] [Related]
14. Degradable lipid nanoparticles with predictable in vivo siRNA delivery activity.
Whitehead KA; Dorkin JR; Vegas AJ; Chang PH; Veiseh O; Matthews J; Fenton OS; Zhang Y; Olejnik KT; Yesilyurt V; Chen D; Barros S; Klebanov B; Novobrantseva T; Langer R; Anderson DG
Nat Commun; 2014 Jun; 5():4277. PubMed ID: 24969323
[TBL] [Abstract][Full Text] [Related]
15. Novel PEGylated Lipid Nanoparticles Have a High Encapsulation Efficiency and Effectively Deliver MRTF-B siRNA in Conjunctival Fibroblasts.
Sanghani A; Kafetzis KN; Sato Y; Elboraie S; Fajardo-Sanchez J; Harashima H; Tagalakis AD; Yu-Wai-Man C
Pharmaceutics; 2021 Mar; 13(3):. PubMed ID: 33805660
[TBL] [Abstract][Full Text] [Related]
16. Development and characterization of a first-in-class adjustable-dose gene therapy system.
Goraltchouk A; Lourie J; Hollander JM; Grace Rosen H; Fujishiro AA; Luppino F; Zou K; Seregin A
Gene; 2024 Aug; 919():148500. PubMed ID: 38663689
[TBL] [Abstract][Full Text] [Related]
17. Nanoparticles as Drug Delivery Systems of RNAi in Cancer Therapy.
Li D; Gao C; Kuang M; Xu M; Wang B; Luo Y; Teng L; Xie J
Molecules; 2021 Apr; 26(8):. PubMed ID: 33921892
[TBL] [Abstract][Full Text] [Related]
18. Optimization of Strategy for Modified mRNA Inducing Cardiac-Specific Expression in Mice.
Huang C; Jia J; Jin K; Zou Y; Tan S; Lu J; Zhu Y; Lin J; Dai Y; Gong H
J Cardiovasc Transl Res; 2023 Oct; 16(5):1078-1084. PubMed ID: 37155138
[TBL] [Abstract][Full Text] [Related]
19. Cartilage-targeting ultrasmall lipid-polymer hybrid nanoparticles for the prevention of cartilage degradation.
Ai X; Duan Y; Zhang Q; Sun D; Fang RH; Liu-Bryan R; Gao W; Zhang L
Bioeng Transl Med; 2021 Jan; 6(1):e10187. PubMed ID: 33532587
[TBL] [Abstract][Full Text] [Related]
20. Rationale and Application of PEGylated Lipid-Based System for Advanced Target Delivery of siRNA.
Ge X; Chen L; Zhao B; Yuan W
Front Pharmacol; 2020; 11():598175. PubMed ID: 33716725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
